Ann: Proposed IPO of China Subsidiary in Hong Kong, page-254

We know GMV are big on research and development and aim to bring innovative mobile health solutions to the market including the Prizma and patch and we know they also look for recurring revenue  model coming from insurance companies  or from the consumer.

Now with the proposed IPO listing, I would imagine they  will have another couple of innovative  ideas to launch into the market place to coincide with the Prizma and the patch.

One that would fit the business base model for tele health  would be COPD   Chronic Obstructive Pulmonary Disease.   

This would be a perfect fit for the company  and for the Hong Kong Listing with access through the green channel for CFDA and establish contacts in China for clinical trials, not to mention the population in China they have access to with MOU  distribution  agreement .

Future is very bright and GMV is leading the change with innovative products for the health sector and the well being  of individuals.